| Ytd | -6.94% | |
| 1y | -1.31% |
| Open | 7.28 | Prev Close | 7.31 | Low | 7.13 | High | 7.35 | Mkt Cap | 201.18M |
| Vol | 51.61K | Avg Vol | 264.98K | EPS | -0.37 | P/E | -19.76 | Forward P/E | -75.83 |
| Beta | 1.07 | Short Ratio | 0.55 | Inst. Own | 24.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 6.39 | 200-d Avg | 7.10 | 1yr Est | 10.00 |
DERM News
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Jou
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.08 per share versus the Zack
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 mill
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o
Company to host conference call to discuss financial results and provide a corporate update on May 1
Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 millio
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims
Journey Medical Corporation (NASDAQ: DERM - Get Free Report) has been assigned an average recommenda
Although the revenue and EPS for Journey Medical (DERM) give a sense of how its business performed i
Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated
Company to host conference call to discuss financial results and provide a corporate update on March
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Friday, 404 stocks made new 52-week lows.
On Thursday, 930 stocks hit new 52-week lows.